Holen Sie sich die Stockscreener-App
2.59
1.97%
0.05
Schlusskurs vom Vortag:
$2.54
Offen:
$2.54
24-Stunden-Volumen:
26,235
Relative Volume:
0.09
Marktkapitalisierung:
$149.56M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-46.12M
KGV:
-2.997
EPS:
-0.8642
Netto-Cashflow:
$-41.02M
1W Leistung:
+7.47%
1M Leistung:
+1.57%
6M Leistung:
+83.69%
1J Leistung:
+64.97%
1-Tages-Spanne:
$2.51
$2.61
1-Wochen-Bereich:
$2.21
$2.61
52-Wochen-Spanne:
$1.165
$2.815
Inflarx N V Stock (IFRX) Company Profile
Vergleichen Sie IFRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IFRX
Inflarx N V
|
2.57 | 149.56M | 0 | -46.12M | -41.02M | -0.8642 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.87 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.68 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
656.70 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.81 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.91 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Inflarx N V Stock (IFRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-04-05 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-02-28 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-10-28 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2021-03-11 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-06 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-10-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2020-04-30 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-06-05 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2019-06-05 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-06-05 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2019-06-05 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-06-05 | Herabstufung | SunTrust | Buy → Hold |
| 2019-01-29 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-12-10 | Eingeleitet | Credit Suisse | Outperform |
| 2018-07-13 | Eingeleitet | BMO Capital Markets | Outperform |
| 2018-06-28 | Eingeleitet | Raymond James | Outperform |
| 2018-06-28 | Eingeleitet | SunTrust | Buy |
| 2018-02-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Inflarx N V Aktie (IFRX) Neueste Nachrichten
Short Interest in InflaRx (NASDAQ:IFRX) Expands By 15.0% - MarketBeat
Adlai Nortye And 2 Other Penny Stocks On US Exchanges To Watch - Simply Wall St
InflaRx (NASDAQ:IFRX) Sees Significant Growth in Short Interest - Defense World
InflaRx (IFRX) Stock Sees After-Market Gains - Stocks Telegraph
InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference - GlobeNewswire
InflaRx to Present at Guggenheim SMID Cap Biotech Conference: Spotlight on Vilobelimab Pipeline - StockTitan
Short Interest in InflaRx (NASDAQ:IFRX) Rises By 15.0% - MarketBeat
InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 Drug - MSN
InflaRx (NASDAQ:IFRX) Earns Buy Rating from HC Wainwright - Defense World
InflaRx stock reiterated at Buy at H.C. Wainwright after EU drug approval - MSN
InflaRx secures European Commission approval for ARDS drug - European Biotechnology News
InflaRx (NASDAQ:IFRX) Given Buy Rating at HC Wainwright - MarketBeat
InflaRx Secures EU Approval for GOHIBIC in Treating COVID-19-Induced ARDS - TipRanks
InflaRx Receives European Commission Approval for GOHIBIC® - GlobeNewswire
InflaRx gets EU okay for Gohibic for COVID-19 respiratory distress - Seeking Alpha
InflaRx's GOHIBIC Makes History as First EU-Approved Treatment for COVID-19 ARDS - StockTitan
InflaRx Announces Participation in January Events in San Francisco - The Manila Times
InflaRx to Present at Major Biotech Events in San Francisco, Showcasing Novel Disease Response Solutions - StockTitan
InflaRx (NASDAQ:IFRX) Sees Large Growth in Short Interest - MarketBeat
InflaRx N.V. (IFRX) Reports Q3 Loss, Tops Revenue Estimates - MSN
US Penny Stocks To Watch In December 2024 - Simply Wall St
Analyst highlights long-term sales growth potential for Inflarx shares with INF904 therapy - Investing.com Nigeria
Analyst highlights long-term sales growth potential for Inflarx shares with INF904 therapy By Investing.com - Investing.com South Africa
InflaRx Advances INF904 for CSU and HS with Phase 2a Study - Dermatology Times
InflaRx (NASDAQ:IFRX) Given "Buy" Rating at HC Wainwright - MarketBeat
InflaRx Begins Phase 2a Trial for Innovative Anti-Inflammatory Drug - TipRanks
InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904 - GlobeNewswire
InflaRx Launches Phase 2a Trial for Billion-Dollar Skin Disease Drug INF904 - StockTitan
InflaRx (NASDAQ:IFRX) Trading 3.8% HigherHere's Why - MarketBeat
InflaRx N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Lucid Capital sets Inflarx NV Buy stock rating on clinical trial potential - Investing.com Canada
10 Best German Stocks To Buy Now - Insider Monkey
Is InflaRx N.V. (IFRX) the Best German Stock to Buy Now? - Insider Monkey
InflaRx receives positive CHMP opinion for SARS-CoV-2-induced acute respiratory distress treatment - MSN
InflaRx's GOHIBIC gets EMA panel nod for COVID-19 ARDS By Investing.com - Investing.com Canada
InflaRx's GOHIBIC gets EMA panel nod for COVID-19 ARDS - Investing.com India
InflaRx’s GOHIBIC gets EMA panel nod for COVID-19 ARDS By Investing.com - ழ தொலைக்காட்சி
InflaRx Receives Positive CHMP Opinion for GOHIBIC® - GlobeNewswire
InflaRx's GOHIBIC Secures Key EU Backing for COVID ARDS Treatment After 24% Mortality Reduction | IFRX Stock News - StockTitan
Finanzdaten der Inflarx N V-Aktie (IFRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.37%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):